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        Introduction 
  Silencing mediator for retinoic acid and thyroid hormone recep-
tor (SMRT) and nuclear receptor corepressor (N-CoR) are two 
closely related transcriptional corepressors that were isolated 
in a search for factors that mediate transcriptional repression 
by nuclear hormone receptors (  Chen and Evans, 1995  ;   Horlein 
et al., 1995  ;   Sande and Privalsky, 1996  ;   Seol et al., 1996  ;   
Ordentlich et al., 1999  ;   Park et al., 1999  ). The repression activ-
ities of SMRT and N-CoR are manifested through association 
with class I and II histone deacetylases (HDACs;   Alland et al., 
1997  ;   Nagy et al., 1997  ;   Huang et al., 2000  ;   Kao et al., 2000  ; 
  Fischle et al., 2002  ). Both SMRT and N-CoR form stable 
complexes with and serve as activating cofactors for HDAC3 
(  Guenther et al., 2001  ;   Fischle et al., 2002  ;   Guenther et al., 
2002  ). In addition to nuclear hormone receptors, SMRT and 
N-CoR also participate in diverse signaling pathways through 
interactions with a variety of transcription factors (  Kao et al., 
1998  ;   Tsai et al., 2004  ;   Goodson et al., 2005  ) and are required 
for normal mammalian development (  Jepsen et al., 2000  ,   2007  ). 
Corepressors have been shown to be involved in several human 
diseases, most notably breast cancers and acute promyelocytic 
leukemias (  Khan et al., 2004  ;   Privalsky, 2004  ). The regulation 
of N-CoR stability has been implicated in several normal and 
aberrant cellular pathways (  Zhang et al., 1998  ;   Khan et al., 
2004  ;   Perissi et al., 2004  ); however, the mechanism of SMRT 
stability regulation has not been clearly defi  ned. 
  SMRT contains at least three different types of functional 
domains. Near the N terminus are two Swi/Ada/N-CoR/TFIID 
motifs in addition to two receptor interaction domains near the 
C terminus (  Privalsky, 2004  ). SMRT also contains at least four 
independent repression domains (RDs; I  –  IV). Because diverse 
proteins are recruited to these RDs, we sought to identify novel 
regulators of SMRT by using RDs III and IV as bait in a yeast 
two-hybrid screen. We identifi  ed the peptidyl-prolyl cis-trans 
isomerase, Pin1, as a SMRT-interacting protein. 
  Pin1 is comprised of an N-terminal protein-binding WW 
domain and a C-terminal peptidyl-prolyl isomerase (PPIase) 
domain (  Lu et al., 1996  ;   Yeh and Means, 2007  ). The WW do-
main of Pin1 binds preferentially to phospho-Ser-Pro  –   (pS-P) 
or phospho-Thr-Pro (pT-P)  –  containing peptide sequences 
(  Ranganathan et al., 1997  ;   Yaffe et al., 1997  ), and the enzyme 
domain also preferentially isomerizes the prolyl bond after 
pT-P or pS-P. Pin1 is frequently localized to nuclei and serves 
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(1,178  –  1,823) fused to the Gal4 DNA-binding domain (DBD) 
was cotransformed with wild-type (WT) Pin1 or one of these 
mutated forms of Pin1, fused to the Gal4 activation domain 
into yeast cells, and tested for   -galactosidase activity. C113A/
A118T retained SMRT binding activity (  Fig. 1 F  , lane 3), sug-
gesting that enzyme activity was not required for binding, 
whereas both WW domain mutants (  Fig. 1 F  , lanes 4 and 5) 
failed to bind SMRT as indicated by loss of    -galactosidase 
activation. GST pull-down assays confirmed the yeast two-
hybrid data by demonstrating that both WT Pin1 and the C113A/
A118T enzymatic mutant bound HA-SMRT (1,178  –  1,823; 
  Fig. 1 G  , lanes 2 and 3), but the S16A/Y23A and R17A WW 
mutants were unable to bind HA-SMRT (1,178  –  1,823;   Fig. 1 G  , 
lanes 4 and 5). Together, these data indicate that the integrity 
of the WW domain but not PPIase activity is essential for 
the Pin1  –  SMRT interaction both in vitro and in yeast two-
hybrid assays. 
  The importance of the WW domain of Pin1 for SMRT 
interaction suggested that phosphorylation of SMRT might be 
involved in this interaction. As an initial test of this hypothesis, 
extracts of HeLa cells expressing HA-SMRT (1,178  –  1,823) 
were incubated with increasing concentrations of calf intestinal 
phosphatase before incubation with GST  –  Pin1.   Fig. 1 H   shows 
that phosphatase treatment of extracts dramatically reduced the 
association of SMRT with Pin1 in vitro (lanes 5 and 6). These 
data indicate that phosphorylation of SMRT is very likely to 
play a critical role in Pin1 binding. 
  Pin1 affects SMRT stability 
  To examine the functional signifi  cance of the SMRT and Pin1 
association, we tested whether ectopic expression of Pin1 af-
fected the transcriptional repressor activity of SMRT. Transient 
transfections showed that Gal4-SMRT (1,050  –  1,823) potently 
repressed basal transcription of a Gal4 reporter (  Fig. 2 A  , lane 1), 
but coexpression of Pin1 reduced SMRT repression activity in 
a dose-dependent manner (  Fig. 2 A  , lanes 2  –  4). Because Pin1 
compromised SMRT repressor activity, we hypothesized that 
Pin1 might modulate SMRT-mediated repression by affecting 
its steady-state levels, as has been shown for other nuclear tar-
gets of Pin1. To test this possibility, SMRT (1,012  –  2,507) and 
Pin1 were coexpressed in CV-1 cells. As shown in   Fig. 2 B  , ex-
pression of Pin1 had a negative, dose-dependent effect on SMRT 
protein levels. We also evaluated the effect of Pin1 on the ex-
pression of endogenous SMRT by immunofl  uorescence micros-
copy. SMRT levels were signifi  cantly decreased in cells transfected 
with FLAG-Pin1 (  Fig. 2 C  , compare c with f), whereas the lev-
els of the closely related corepressor N-CoR did not change 
( Fig. 2 C , i and l). We confi  rmed these observations using siRNA 
targeting Pin1.   Fig. 2 D   shows that when endogenous Pin1 lev-
els were decreased by siRNA, endogenous SMRT protein levels 
increased (lanes 2 and 3), whereas HDAC3 levels showed neg-
ligible differences. Together, these data suggest that Pin1 regu-
lates SMRT abundance. 
  To determine whether SMRT interaction or the prolyl 
isomerase activity of Pin1 is critical for modulating the tran-
scriptional repression activity of SMRT, the Pin1 mutants de-
scribed in   Fig. 1 E   were used. We found that all three Pin1 
as a regulatory protein for a variety of proteins associated with 
transcription, including cyclin E1, c-Myc, p53, SRC-3, and 
the retinoic acid receptor (  Zacchi et al., 2002  ;   Zheng et al., 
2002  ;   Yeh et al., 2004, 2006  ;   Brondani et al., 2005  ;   Yi et al., 
2005  ;   van Drogen et al., 2006  ). In the case of all of these tran-
scription factors, the binding of Pin1 to a phosphorylated mo-
tif regulates the stability of its target protein. In this study, we 
characterize the interaction between SMRT and Pin1. We fi  nd 
that Pin1 binds to phosphorylated SMRT, identify the relevant 
protein kinase as Cdk2, and show that Cdk2 and Pin1 facilitate 
the degradation of SMRT. We also demonstrate that Cdk2 and 
Pin1 are required for ErbB2-mediated degradation of SMRT 
protein. Together, our data reveal a novel mechanism by which 
SMRT is regulated in cells. 
  Results 
  SMRT interacts with Pin1 in a 
phosphorylation-dependent manner 
  In a search for proteins that may regulate SMRT activity, yeast 
two-hybrid screens were performed using pGal4-SMRT (in-
cluding RDs III and IV) as bait against a library derived from 
17-d-old mouse embryos. Among the interacting clones, mouse 
Pin1 was isolated six times, with the longest insert encoding 
full-length Pin1. To test whether exogenous SMRT and Pin1 
interact in mammalian cells, we used extracts of transfected 
mammalian cells for coimmunoprecipitations (  Fig. 1 A  ). Using 
    -HA antibodies, we were able to coimmunoprecipitate FLAG-
Pin1 with HA-SMRT (1,178  –  1,823;   Fig. 1 A  , lane 2), indicating 
that these proteins interact. This interaction was confi  rmed by 
showing that endogenous SMRT was able to bind GST  –  Pin1 
(  Fig. 1 B  , lane 3) but not GST alone (  Fig. 1 B  , lane 2). Because 
both Pin1 and 14-3-3 proteins interact with substrates in a 
phosphorylation-dependent manner (  Yaffe and Elia, 2001  ), we 
tested whether 14-3-3 proteins were also able to interact with 
SMRT (  Fig. 1 C  ). GST  –  Pin1 (  Fig. 1 C  , lane 2) but not GST  –
 14-3-3    (  Fig. 1 C  , lane 3) was able to pull down HA-SMRT 
(1,178  –  1,823). Finally, Pin1 was also able to coimmunoprecipi-
tate endogenous SMRT (  Fig. 1 D  , lane 3), whereas protein A 
beads alone were unable to do so (  Fig. 1 D  , lane 2). These data 
confi  rm Pin1 to be a SMRT-interacting protein both in vitro and 
in mammalian cells and verify the interaction originally ob-
served in the yeast two-hybrid screen. 
  Pin1 is a 163  –  amino acid protein that contains two 
known functional domains, a WW domain (amino acids 6  –  37) 
and a PPIase domain (amino acids 54  –  163;   Fig. 1 E  ). Pin1 as-
sociates with its interacting partners through the WW domain, 
a protein  –  protein interaction module that has been shown 
to bind specifi  cally to pS-P or pT-P dipeptide motifs (  Sudol 
et al., 2001  ;   Yaffe and Elia, 2001  ). Mutations of Pin1 such as 
S16A/Y23A and R17A are unable to bind pS/pT-P motifs and 
thus abrogate this binding (  Shen et al., 1998  ;   Lu et al., 1999  ). 
We generated these mutants of Pin1 as well as a C113A/A118T 
mutant that has decreased PPIase activity (  Shen et al., 1998  ) 
by site-directed mutagenesis, and yeast two-hybrid assays 
were used to determine whether the WW domain or isomer-
ase activity is critical for SMRT interaction (  Fig. 1 F  ). SMRT 51  REGULATION OF SMRT STABILITY   • Stanya et al. 
Pin1 
   /    MEFs. MEF cells were pulse labeled with [ 
35 S]methionine 
and [ 
35  S]cysteine followed by a chase with unlabeled amino 
  acids. Cell extracts were subjected to immunoprecipitation with 
SMRT antibodies and autoradiography.   Fig. 2 H   shows that 
SMRT was more stable in Pin1 
   /     MEFs than in Pin 
+/+   MEFs. 
To confi  rm that the effect on SMRT half-life was because of 
Pin1, we transfected HeLa cells stably expressing short hairpin 
RNA against Pin1 (  Reineke et al., 2008  ) with either WT or mu-
tant Pin1 (C113A/A118T).   Fig. 2 I   shows that WT Pin1 de-
creased SMRT stability, whereas the mutant had little effect. 
From these data, we conclude that Pin1 is a SMRT-interacting 
protein that regulates SMRT protein levels by modulating 
SMRT half-life. 
  Mapping Pin1 interaction sites 
  To elucidate the mechanism by which Pin1 modulates SMRT 
stability, we fi  rst mapped the pS/T-P motifs in SMRT responsi-
ble for Pin1 binding. SMRT deletion constructs fused to the 
yeast Gal4 DBD (  Fig. 3 A  , left) were used in yeast two-hybrid 
assays. As shown in   Fig. 3 A  , we found that Pin1 does not inter-
act with the N- or C-terminal regions of SMRT; rather, Pin1 
specifi  cally interacts with amino acids 1,178  –  1,823 of SMRT 
(containing RDs III and IV). These results were confi  rmed by GST 
pull downs (  Fig. 3 B  ) showing that Pin1 interacts specifi  cally with 
mutants were defective in their ability to relieve Gal4-SMRT 
(1,050  –  1,823) activity to varying degrees (  Fig. 2 E  , lanes 3  –  5), 
indicating that both binding (from the WW domain) and enzy-
matic activity (from the PPIase domain) are required for Pin1 to 
affect SMRT-mediated repression. Because ectopic expression 
of Pin1 affected SMRT protein levels, we next examined the ef-
fect of the Pin1 mutants on SMRT protein levels. To test this, 
FLAG-SMRT (1,178  –  1,823) was cotransfected into cells with 
or without WT or mutant forms of HA-Pin1. As seen in   Fig. 2 F  , 
WT HA-Pin1 decreased SMRT steady-state levels (lane 2) to a 
much greater extent than did any of the three mutants (lanes 3  – 5). 
Together, these data indicate that both domains of Pin1 partici-
pate in the regulation of SMRT accumulation. Additionally, it is 
likely that a Pin1-dependent decrease in SMRT protein levels is 
responsible for the loss of repression activity (  Fig. 2, A and E  ). 
  To further examine the effect of ectopic Pin1 on SMRT, 
we used Pin1 
   /     mouse embryonic fi  broblast (MEF) cells (  Yeh 
et al., 2006  ). Consistent with previous data, ectopic expression 
of FLAG-Pin1 in Pin1 
   /     MEFs dramatically decreased HA-
SMRT (1,178  –  1,823) protein levels in a dose-dependent man-
ner (  Fig. 2 G  ), indicating that this mechanism is active in MEFs. 
We then determined whether the presence of endogenous Pin1 
altered SMRT stability by performing metabolic pulse-chase 
  labeling assays to measure the half-life of SMRT in Pin1 
+/+   and 
  Figure 1.       Pin1 is a SMRT-associating protein.   
(A) Transfected SMRT and Pin1 interact in 
mammalian cells. HeLa cells were transfected 
with either FLAG-Pin1 alone or with both FLAG-
Pin1 and HA-SMRT (1,178  –  1,823). WCEs 
expressing these proteins were subjected to 
coimmunoprecipitation with     -HA  –  conjugated 
agarose beads followed by immunoblotting 
with the indicated antibodies. (B) Pin1 inter-
acts with SMRT in vitro. Puriﬁ  ed, immobilized 
GST  –  Pin1 fusion protein was incubated with 
HeLa nuclear extracts, and bead fractions 
were subjected to immunoblotting with     -SMRT 
antibodies. (C) SMRT interacts with Pin1 but 
not 14-3-3    . GST pull downs were performed 
using puriﬁ  ed  GST  –  Pin1, GST  –  14-3-3    , and 
HeLa WCEs expressing HA-SMRT (1,178  –
  1,823). Top, immunoblotting with     -HA; bottom, 
Coomassie staining. (D) Endogenous SMRT 
and Pin1 interact in mammalian cells. HeLa 
nuclear extracts were subjected to coimmuno-
precipitation with Pin1 antibodies and immuno-
blotting with the indicated antibodies. Unrelated 
lanes were removed. (E) Schematic representa-
tion of human Pin1. Point mutations used in this 
study are indicated by *. Pin1 contains both 
a WW domain and a PPIase domain. Amino 
acids are indicated by numbers. (F) The Pin1 
WW domain is critical for interaction with 
SMRT in yeast. Y190 cells expressing GAL4 
DBD SMRT (1,178  –  1,823) and the indicated 
GAL4 activation domain Pin1 constructs were 
subjected to     -galactosidase assays as de-
scribed in Materials and methods. Error bars 
represent   ±  SD. (G) The Pin1 WW domain is 
essential for SMRT association in vitro. GST pull 
downs were performed using the indicated 
GST  –  Pin1 proteins and HeLa WCEs express-
ing HA-SMRT (1,178  –  1,823). Top, immuno-
blotting with     -HA; bottom, Coomassie staining. (H) Phosphatase treatment disrupts the SMRT  –  Pin1 interaction in vitro. HeLa WCEs expressing HA-SMRT 
(1,178  –  1,823) were treated with increasing amounts of calf intestinal phosphatase followed by GST pull downs. Top, immunoblotting with     -HA; bottom, 
Coomassie staining.     JCB • VOLUME 183 • NUMBER 1 • 2008  52
  Figure 2.       Pin1 down-regulates SMRT protein levels.   (A) Overexpression of Pin1 relieves SMRT repression. CV-1 cells were transiently transfected with Gal4-
SMRT (1,050  –  1,823), increasing amounts of Pin1, and a thymidine kinase  –  luciferase reporter. Luciferase activity was measured 36  –  48 h after transfection; all 
experiments were performed in triplicate. Error bars represent   ±  SD. (B) Overexpression of Pin1 has a negative effect on SMRT steady-state levels. SMRT (1,012  –
  2,507), FLAG-Pin1, and GFP were cotransfected into CV-1 cells. WCEs were subjected to immunoblotting with the indicated antibodies. (C) Ectopic expression 
of Pin1 affects endogenous SMRT levels in MCF-7 cells. Cells were transfected with FLAG-Pin1 or FLAG-vector and immunostained with the indicated antibodies 
24 h after transfection. (top) DAPI staining; (middle)     -FLAG staining; (bottom) SMRT or N-CoR staining. Arrowheads indicate transfected cells. Bar, 5   μ  m. (D) siRNA-
mediated knockdown of Pin1 increases SMRT protein levels. HeLa cells were transfected with either a control oligonucleotide or one of two Pin1-targeting siRNAs. 
Cells were harvested 72 h later, and WCEs were subjected to immunoblotting with the indicated antibodies. (E) Pin1 mutants lose the ability to relieve SMRT 
repression. CV-1 cells were transiently transfected with Gal4-SMRT (1,050  –  1,823), Pin1 WT or mutants, and a thymidine kinase  –  luciferase reporter. Luciferase 
activity was measured 36  –  48 h later; all experiments were performed in triplicate. Error bars represent   ±  SD. (F) Pin1 mutants lose the ability to down-regulate 
SMRT levels. CV-1 cells were cotransfected with FLAG-SMRT (1,178  –  1,823) and HA-tagged Pin1 WT or mutants. WCEs were subjected to immunoblotting with 
the indicated antibodies. (G) Exogenous overexpression of Pin1 in Pin1 
    /      MEFs decreases SMRT levels. HA-SMRT (1,178  –  1,823), FLAG-Pin1, and GFP were 
cotransfected into Pin1 
    /      MEFs, and immunoblotting was performed using the indicated antibodies. (H) SMRT half-life is increased in Pin1 
    /      MEFs. Pin1 
+/+   and 
Pin1 
    /      MEFs were pulse labeled with [ 
35  S]methionine and [ 
35  S]cysteine and chased with cold growth medium as described in Materials and methods. WCEs 
were prepared and subjected to immunoprecipitation, and protein levels were detected by autoradiography. Left,  
35  S autoradiography; right, quantiﬁ  cation of 
immunoprecipitated  
35  S-labeled SMRT. Error bars represent   ±  SD. (I) SMRT destabilization requires Pin1 isomerase activity. HeLa cells stably expressing shRNA 
against Pin1 were transfected with SMRT (1,178  –  1,823) and either WT Pin1 or Pin1 (C113A/A118T) and treated with 100   μ  g/ml CHX for the indicated times, 
and immunoblots were performed using the indicated antibodies. Left, immunoblot; right, quantiﬁ  cation of SMRT levels normalized to actin levels.     53  REGULATION OF SMRT STABILITY   • Stanya et al. 
in complete loss (lane 9). Among the phosphorylated sites, 
S1241 and S1469 are both consensus Cdk target sites of the 
motif S/T-P-X-R/K. An additional possible Cdk site at T1445 
was not phosphorylated based on the mass spectrometry anal-
ysis (  Fig. 3 C  , Cdk sites indicated by     ). Because loss of two 
potential Cdk sites abrogated GST  –  Pin1 interaction (S1241 
and T1445;   Fig. 3 D  ), we next investigated whether Pin1 could 
interact with SMRT phosphorylated at those three Cdk sites. 
We performed pull downs with GST  –  Pin1 and immunoblotted 
using phosphospecifi  c antibodies for the three Cdk sites (  Fig. 3 E  ). 
We found that GST  –  Pin1 interacted with HA-SMRT (1,178  –
 1,823) that was phosphorylated at these three Cdk sites ( Fig. 3 E , 
lanes 6, 9, and 12). Collectively with the phosphatase data 
(  Fig. 1 H  ), these results reveal that phosphorylation of SMRT 
is critical for its interaction with Pin1. 
the SMRT fragment corresponding to RDs III and IV (  Fig. 3 B  , 
lane 6) but neither the N- nor C-terminal fragments (  Fig. 3 B  , 
lanes 3 and 9). 
  Because the interaction between SMRT and Pin1 is de-
pendent on the phosphorylation status of SMRT (  Fig. 1 H  ), 
we used mass spectrometry to identify in vivo phosphoryla-
tion sites in FLAG-SMRT (1,178  –  1,823). Four phosphopep-
tide sequences were identifi  ed, indicating that S1241, T1373, 
T1469, S1762, and S1765 were phosphorylated (  Fig. 3 C  ,   * ). 
We used N-terminal deletion constructs (1,281  –  1,823 and 1,463  –
  1,823;   Fig. 3 C  ) expressed in HeLa cells to determine whether 
any of the identifi  ed phosphorylation sites were critical for 
interaction with GST  –  Pin1.   Fig. 3 D   shows that deletion past 
the fi  rst phosphorylation site (S1241) resulted in some loss of 
GST  –  Pin1 binding (lane 6), whereas further deletion resulted 
  Figure 3.       Mapping the Pin1 interaction domain in SMRT.   (A) Yeast two-hybrid mapping of the Pin1 interaction domain. Left, diagram of Gal4-DBD-SMRT 
fragments used; right, normalized     -galactosidase activity. Amino acids are indicated by numbers. Error bars represent   ±  SD. (B) GST pull down mapping 
of Pin1-interacting regions in SMRT. HeLa WCEs expressing the indicated HA-SMRT constructs were subjected to pull downs using GST  –  Pin1 and immuno-
blotted with anti-HA antibodies. (C) Schematic diagram of SMRT showing in vivo phosphorylation sites as mapped by mass spectrometry (  *  ), Cdk consen-
sus motifs (    ), and deletion constructs used in   Fig. 3 D  . Amino acids are indicated by numbers. (D) GST pull downs of N-terminal deletions of HA-SMRT. 
HeLa WCEs expressing the indicated HA-SMRT constructs were subjected to pull downs using GST  –  Pin1 and immunoblotted with anti-HA antibodies. 
(E) Phosphorylated SMRT interacts with Pin1 in vitro. HeLa WCEs expressing HA-SMRT (1,178  –  1,823) were subjected to pull downs using GST  –  Pin1 and 
immunoblotting with the indicated antibodies. WB, Western blot.     JCB • VOLUME 183 • NUMBER 1 • 2008  54
Pin1 binding in vitro (  Fig. 5 E  , lane 5). Pin1 binding was not ob-
served in the absence of kinase (  Fig. 5 E  , lane 3), indicating that 
phosphorylation is required for the interaction. These data indicate 
that Cdk2 can bind and phosphorylate SMRT and is likely to be a 
kinase that facilitates Pin1 binding by generating pS/T-P sites. 
  If Cdk2 generates Pin1-binding sites in vivo, we hypothe-
sized that Cdk2 may have an effect similar to that of Pin1 on SMRT 
stability. To test this hypothesis, we coexpressed Cdk2 and cyclin A 
in HeLa cells to determine the effects on SMRT steady-state 
levels. As seen in   Fig. 6 A  , Cdk2 and cyclin A coexpression 
decreased HA-SMRT (1,012  –  2,507) protein levels (lane 2). 
Additionally, overexpression of Cdk2 and cyclin A increased 
HA-SMRT (1,012  –  2,507) phosphorylation at two of the three pu-
tative Cdk sites (  Fig. 6 B  , lane 2) when these extracts were normal-
ized for HA-SMRT (1,012  –  2,507) levels. Consistent with these 
results, expression of a dominant-negative (DN) mutant form 
of Cdk2 (D145N) led to the accumulation of HA-SMRT (1,012  –
  2,507) protein (  Fig. 6 C  ) and a marked decrease in HA-SMRT 
(1,012 – 2,507) phosphorylation at the predicted Cdk sites as visual-
ized by immunoblotting with phosphospecifi  c antibodies ( Fig. 6 D ). 
We further confi  rmed these observations using siRNA targeting 
Cdk2.   Fig. 6 E   shows that endogenous SMRT levels increase when 
Cdk2 levels are knocked down. Furthermore, Cdk2 overexpression 
signifi  cantly decreased steady-state protein levels of WT HA-
SMRT  (1,178 – 1,823)  but  not  HA-SMRT  3 ×   (1,178 – 1,823),  indi-
cating that Cdk phosphorylation sites are critical for this regulation 
( Fig. 6 F , compare lanes 1 and 2 with lanes 3 and 4). Together, these 
data indicate that Cdk2 is a critical regulator of SMRT stability. 
  To examine whether Cdk2-mediated SMRT destabilization 
is dependent on Pin1, we used siRNA targeting Pin1 to deplete 
endogenous Pin1 from cells.  Fig. 6 G  shows that Pin1 knockdown 
blocked the ability of Cdk2  –  cyclin A to decrease steady-state lev-
els of HA-SMRT (1,178  –  1,823; compare lanes 1 and 2 with lanes 3 
and 4). Furthermore, a Pin1 mutant with decreased isomerization 
activity, C113A/A118T, also blocked the destabilization effects of 
Cdk2 on HA-SMRT (1,178  –  1,823;   Fig. 6 H  ). These data indicate 
that endogenous Pin1 contributes to HA-SMRT (1,178  –  1,823) 
degradation through a Cdk2-dependent pathway. 
 Because deletion of Cdk sites in SMRT leads to loss of Pin1 
binding, we next investigated the importance of these sites by 
generating a Ser → Ala and Thr → Ala triple mutant SMRT (SMRT 
3 × ;   Fig.  3  C ,    ).  The  phosphospecifi  c antibodies were unable to 
detect this mutant (  Fig. 4 A  , lane 2), confi  rming the specifi  city of 
the antibodies. SMRT 3  ×   (1,012  –  2,507) was much less able to 
interact with GST  –  Pin1 (  Fig. 4 B  , lane 6) than the WT, indicating 
that intact Cdk consensus sites are critical for interaction with 
Pin1. In addition, we also generated double and single Cdk mu-
tants in SMRT and found that single mutations had no signifi  cant 
effect on Pin1 binding, whereas the double mutants showed only 
slight decreases in Pin1 binding (unpublished data). SMRT 3  ×   
(1,178  –  1,823) was also more stable than the WT protein, as 
shown by cycloheximide (CHX) treatment in HeLa cells ( Fig. 4 C ). 
These data indicate that consensus Cdk sites in SMRT are phos-
phorylated and critical for the SMRT  –  Pin1 interaction. 
  SMRT is a Cdk2 target 
  Because mutation of putative Cdk sites in SMRT abrogated both 
Pin1 binding and its effect on SMRT stability, we hypothesized 
that phosphorylation by Cdk  –  cyclin complexes might be respon-
sible for generating Pin1-binding sites.  Fig. 5 A  shows that endog-
enous Cdk2 and its activating cyclins A and E were capable of 
coimmunoprecipitating endogenous SMRT from HeLa nuclear 
extracts (lanes 3 – 5). However, cyclin E did not effi  ciently immuno-
precipitate Cdk2. Interestingly, neither N-CoR nor HDAC3 was 
detected in these immunocomplexes. To confi  rm these obser-
vations, we coexpressed HA-SMRT (1,178  –  1,823) and Cdk2 in 
mammalian cells. As expected, Cdk2 coimmunoprecipitated with 
SMRT (  Fig. 5 B  , lane 3). Furthermore, Cdk2 phosphorylated WT 
GST-SMRT (1,178  –  1,578;   Fig. 5 C  , lane 2) but not the GST-3  ×   
mutant (1,178  –  1,578;   Fig. 5 C  , lane 4) or a GST  –  SMRT (1,560  –
  1,823) fragment that does not contain any consensus Cdk 
phosphorylation sites (  Fig. 5 C  , lane 6), indicating that S1241, 
T1445, and S1469 are required for Cdk2-dependent phosphoryl-
ation in vitro. Additionally, Cdk2 specifi  cally phosphorylated all 
three of the predicted Cdk sites in vitro (  Fig. 5 D  , lane 2). Addition 
of active Cdk2 to purifi   ed  His6-SMRT  (1,178 – 1,823)  facilitated 
  Figure 4.       Mutations of Cdk sites in SMRT 
disrupt Pin1 interaction.   (A) Phosphospeciﬁ  c 
antibodies recognize WT but not mutant SMRT. 
HeLa cells were transfected with either WT 
HA-SMRT (1,178  –  1,823) or a 3  ×   mutant 
(S1241A/T1445A/S1469A), and WCEs were 
prepared for immunoblotting with the indi-
cated antibodies. (B) Mutation of Cdk sites in 
SMRT disrupts Pin1 interaction in vitro. HeLa 
cells were transfected with HA-SMRT WT 
(1,012  –  2,507) or the 3  ×   mutant, and WCEs 
were subjected to pull downs with GST  –  Pin1 
and immunoblotted with     -HA antibodies. 
(C) Mutation of Cdk sites stabilizes SMRT. HeLa 
cells were transfected with HA-SMRT (1,178  –
  1,823) or the 3  ×   mutant and treated with 
100     g/ml CHX for the indicated times. WCEs 
were immunoblotted with the indicated anti-
bodies. Left, immunoblot; right, quantiﬁ  cation 
of SMRT levels normalized to actin levels.     55  REGULATION OF SMRT STABILITY   • Stanya et al. 
for 72 h followed by RNA extraction and RT-PCR. We exam-
ined the expression of known ER     gene targets such as c-Myc 
and progesterone receptor (PR). As shown in   Fig. 7 E  , tamoxi-
fen treatment repressed both c-Myc and PR expression but not 
the control gene 36B4 (lanes 1 and 2), whereas knockdown of 
SMRT compromised tamoxifen-mediated repression of both 
c-Myc and PR expression (lanes 3 and 4), and knockdown of Pin1 
or Cdk2 increased repression of both genes (lanes 5  –  8). Inter-
estingly, knockdown of Pin1 led to increases in c-Myc and PR 
transcription, whereas Cdk2 knockdown increased PR tran-
script levels. These data indicate that SMRT is critical for ER   -
dependent gene repression in response to tamoxifen. Because 
tamoxifen suppresses cell proliferation of BT-474 cells, we also 
examined whether knockdown of SMRT, Pin1, or Cdk2 affected 
proliferation rates.   Fig. 7 F   shows that knockdown of SMRT in-
creased cell proliferation when compared with siControl, whereas 
Cdk2 showed a slight decrease in cell proliferation compared 
with the control. Together, these data indicate that control of 
SMRT stability likely has multiple cellular effects, including 
gene expression and cell proliferation. 
  Discussion 
  Here we show that the corepressor SMRT interacts with both 
the PPIase Pin1 and the cell cycle  –  dependent kinase Cdk2, two 
proteins that are downstream effectors of Her2/Neu/ErbB2 
(  Neve et al., 2000  ;   Ryo et al., 2002  ). Pin1 requires an intact 
WW domain and phosphorylation of SMRT for this interaction. 
  ErbB2 destabilizes SMRT protein level 
  Because ErbB2/Her2/Neu has been shown to increase Cdk activ-
ity and up-regulate Pin1 expression in certain breast cancers ( Ryo 
et al., 2002  ;   Timms et al., 2002  ), we next investigated whether 
ErbB2 activity could modulate SMRT half-life. Using heregulin, 
a small protein activator of ErbB2, and AG825, a chemical inhibi-
tor of ErbB2, we analyzed SMRT half-life. MCF-7 cells show a 
decrease in SMRT half-life when treated with heregulin as com-
pared with the vehicle control (  Fig. 7 A  ). Furthermore, in BT-474 
cells that overexpress ErbB2, both transfected HA-SMRT (1,012 –
  2,507;   Fig. 7 B  , right) and endogenous SMRT (  Fig. 7 B  , left) 
half-life decreased upon heregulin treatment. Conversely, upon 
treatment with the ErbB2 inhibitor AG825, both SMRT half-life 
(  Fig. 7 B  ) and SMRT protein levels increased (  Fig. 7 C  ). Finally, 
to test whether ErbB2 acts upstream of Cdk2 and Pin1, we used 
siRNA targeting either Pin1 or Cdk2 to evaluate SMRT protein 
levels. BT-474 breast cancer cells were transfected with siRNAs 
followed by treatment with heregulin.   Fig. 7 D   shows that hereg-
ulin decreased SMRT protein levels by half (lanes 1 and 2), 
whereas siRNA targeting either Pin1 or Cdk2 blocked this effect 
(lanes 3  –  6). Collectively, these results indicate that ErbB2 signal-
ing upstream of Cdk2 and Pin1 is a potential regulatory cascade 
involved in regulating the stability of SMRT. 
  To further characterize the role of the Cdk2- and Pin1-
dependent SMRT degradation pathway in tamoxifen resistance, 
we treated BT-474 cells with siRNA targeting either SMRT, 
Pin1, or Cdk2 to examine gene expression. After siRNA treat-
ment, cells were treated with or without 4-hydroxytamoxifen 
  Figure 5.       Cdk2 interacts with and phosphor-
ylates SMRT to generate Pin1-binding sites. 
  (A) Endogenous SMRT coimmunoprecipitates 
with Cdk2 in HeLa nuclear extracts. Coimmuno-
precipitations were performed as described in 
  Fig. 1 D   using the indicated antibodies (top) 
followed by immunoblotting with the indicated 
antibodies (left). Unrelated lanes were re-
moved. (B) Exogenous Cdk2 and SMRT inter-
act. HA-SMRT (1,178  –  1,823) and FLAG-Cdk2 
were cotransfected into HeLa cells. Coimmuno-
precipitations were performed as in   Fig. 1 A   and 
immunoblotted with the indicated antibodies. 
(C) Cdk2 phosphorylates SMRT in vitro. Puri-
ﬁ   ed GST-SMRT proteins (WT 1,178  –  1,578, 
3  ×   mutant 1,178  –  1,578, and WT 1,560  –
  1,823) were incubated with puriﬁ  ed Cdk2 and 
[ 
32  P]ATP. Samples were resolved by SDS-PAGE 
and transferred to a polyvinylidene diﬂ  uoride 
membrane before autoradiography. Top, auto-
radiography; bottom, Coomassie staining; 
*, GST-SMRT (1,178  –  1,578); **, GST-SMRT 
(1,560  –  1,823). (D) Cdk2 phosphorylates 
S1241, T1445, and S1469 of SMRT. In vitro 
kinase assays were performed as aforemen-
tioned using GST-SMRT (1,178  –  1,588), Cdk2, 
and unlabeled ATP. Immunoblotting was per-
formed with the indicated antibodies. (E) Cdk2 
phosphorylation of SMRT generates Pin1-
binding sites. His6-SMRT (1,178  –  1,823) was 
subjected to in vitro kinase assays as described 
in D. After kinase reactions, samples were 
subjected to GST pull downs with GST  –  Pin1. 
Immunoblotting was performed with the indi-
cated antibodies. Unrelated lanes were removed.     JCB • VOLUME 183 • NUMBER 1 • 2008  56
(  Fig. 7 G  ). Consistent with these observations, activation of 
Her2/Neu/ErbB2 promotes SMRT degradation, whereas in-
hibition of Her2/Neu/ErbB2 stabilizes SMRT. These data suggest 
Cdk2 phosphorylates SMRT at consensus Cdk motifs to gener-
ate Pin1-binding sites and consequently targets SMRT for deg-
radation, the latter also requiring the PPIase activity of Pin1 
  Figure 6.       Cdk2 stimulates SMRT phosphorylation in HeLa cells.   (A) Coexpression of Cdk2 and cyclin A decreases SMRT steady-state levels. HeLa cells 
were cotransfected with HA-SMRT (1,012  –  2,507), GFP, FLAG-Cdk2, and FLAG  –  cyclin A as indicated. Unrelated lanes were removed. (B) Coexpression 
of Cdk2 and cyclin A increases SMRT phosphorylation. HeLa cells were transfected as in A and treated with 20 nM calyculin A for 1 h before harvest. 
Unrelated lanes were removed. (C) DN Cdk2 increases SMRT steady-state levels. HeLa cells were transfected with HA-SMRT (1,012  –  2,507), GFP, and 
FLAG-DN-Cdk2 (D145N), and WCEs were immunoblotted with the indicated antibodies. (D) DN Cdk2 decreases SMRT phosphorylation. HeLa cells 
were transfected as in C and treated with 20 nM calyculin A 1 h before harvest. WCEs were subjected to immunoblotting with indicated antibodies. 
(E) siRNA-mediated knockdown of Cdk2 increases SMRT protein levels. Transfections were performed as in   Fig. 2 D  . (F) Cdk2 overexpression does not affect 
mutant SMRT protein levels. HeLa cells were cotransfected with HA-SMRT (1,188  –  1,833) 3  ×   mutant, GFP, FLAG-Cdk2, and FLAG  –  cyclin A as indicated. 
(G) Endogenous Pin1 is required for Cdk2-mediated SMRT degradation. HeLa cells were cotransfected with HA-SMRT (1,188  –  1,833), GFP, FLAG-Cdk2, 
FLAG  –  cyclin A, and either siRNA-targeting Pin1 or control oligonucleotides as indicated. (H) Mutant Pin1 can block Cdk2-mediated SMRT degradation. 
HeLa cells were cotransfected with HA-SMRT (1,188  –  1,833), GFP, FLAG-Cdk2, FLAG  –  cyclin A, and either WT HA-Pin1 or the C113A/A118/T mutant as 
indicated. (A  –  H) WCEs were subjected to immunoblotting with the indicated antibodies.     57  REGULATION OF SMRT STABILITY   • Stanya et al. 
ative activity of tamoxifen therefore depends on the relative 
abundance of corepressors and coactivators (  Graham et al., 
2000a  ,  b  ;   Fujita et al., 2003  ). Indeed, both SMRT and N-CoR 
are required for the antiproliferative effects of tamoxifen in 
MCF-7 cells (  Keeton and Brown, 2005  ). Additionally, certain 
coactivators such as AIB1/SRC-3 have been shown to be up-
regulated in ErbB2-positive breast tumors, which would further 
disrupt the corepressor/coactivator ratio (  Osborne et al., 2003  ), 
and it is interesting that SRC-3 turnover is also regulated by 
Pin1 (  Yi et al., 2005  ) and reversible phosphorylation (  Wu et al., 
2007  ). Here we show that SMRT protein levels can be modulated 
by the oncogene Her2/Neu/ErbB2 to alter the ratio of corepressors 
a concerted regulation of a transcriptional corepressor initiated 
by extracellular stimuli functioning to activate a transmembrane 
tyrosine kinase receptor. 
  In tamoxifen-responsive breast cancer cells, tamoxifen-
bound ER     recruits corepressor complexes to inhibit ER   -
target gene expression ( Smith et al., 1997 ;  Fleming et al., 2004 ). 
Decreased levels of corepressors correlate with acquired tamox-
ifen resistance (  Lavinsky et al., 1998  ), whereas high expression 
of coactivators favors an agonist effect for tamoxifen (  Shang 
and Brown, 2002  ;   Shou et al., 2004  ). Overexpression of SMRT 
or N-CoR promotes the antagonist activity of tamoxifen in tran-
sient transfection assays (  Jackson et al., 1997  ). The antiprolifer-
  Figure 7.       ErbB2 attenuates SMRT levels 
in breast cancer cells.   (A) SMRT half-life in 
MCF-7 cells. Cells were pulse labeled with 
[ 
35  S]methionine and [ 
35  S]cysteine and chased 
with cold growth medium. Additionally, cells 
were treated with 100 ng/ml heregulin or a 
vehicle control for 30 min before labeling. 
Top,  
35  S autoradiography; bottom, quantiﬁ  ca-
tion of immunoprecipitated  
35  S-labeled SMRT. 
(B) SMRT half-life in BT-474 cells. Experiments 
were performed according to the description 
in A with the addition of 0.1    M AG825 treat-
ment. Unrelated lanes were removed. Left, 
endogenous SMRT; right, transfected HA-SMRT 
(1,012  –  2,507); top,  
35  S autoradiography; 
bottom, quantiﬁ   cation of immunoprecipitated 
 
35  S-labeled SMRT. (C) AG825 treatment in-
creases SMRT protein levels. BT-474 cells were 
treated with 0.1     M AG825 or vehicle control 
for 48 h. WCEs were immunoblotted with the 
indicated antibodies. (D) ErbB2 controls SMRT 
levels through a Pin1- and Cdk2-dependent 
pathway. BT-474 cells were transfected with 
siRNAs for 24 h followed by treatment with 
100 ng/ml heregulin for 48 h. WCEs were 
subjected to immunoblotting with the indicated 
antibodies. Quantiﬁ  cation of SMRT levels normal-
ized to actin is shown below the blot; quantiﬁ  -
cation was performed in Photoshop. (E) SMRT 
is required for ER    -dependent repression in 
response to tamoxifen. BT-474 cells were 
transfected with siRNAs for 48 h followed by 
treatment with 100 nM 4-hydroxytamoxifen for 
72 h. Total RNA was harvested followed by 
cDNA generation. RT-PCR was performed us-
ing primers targeting the indicated genes. Top, 
ethidium bromide staining; bottom, quantiﬁ  ca-
tion of three sets of experiments for each gene. 
(F) SMRT is required for tamoxifen-dependent 
inhibition of cell proliferation. BT-474 cells were 
transfected with siRNAs as in E. 48 h after 
transfection, cells were counted, split evenly onto 
plates, and treated with 100 nM 4-hydroxy-
tamoxifen for the indicated times. Proliferation 
was measured every 24 h. Error bars repre-
sent   ±  SD. (G) Model of SMRT regulation by 
Pin1 and Cdk2. SMRT is phosphorylated by 
Cdk2  –  cyclin A complexes. These phosphoryl-
ation sites serve as binding sites for Pin1, which 
subsequently targets SMRT for degradation. 
Additionally, Pin1 may act in other pathways 
to affect tamoxifen resistance, as knockdown 
of Pin1 in BT-474 cells did not signiﬁ  cantly up-
regulate SMRT protein levels.     JCB • VOLUME 183 • NUMBER 1 • 2008  58
sensitivity through other pathways independent of controlling 
SMRT protein levels. 
  Pin1 is capable of promoting both stabilization and degra-
dation of several target proteins ( Yeh and Means, 2007 ); however, 
in many cases, the mechanisms underlying these opposing activ-
ities remain largely unexplored. In the case of c-Myc, Pin1 pro-
motes a conformational change that allows rapid dephosphorylation 
of a specifi  c threonine residue that is required for the binding of a 
ubiquitin E3 ligase (  Yeh et al., 2004  ). In other cases, the confor-
mational switch to certain prolyl isomers (cis or trans) also makes 
the target protein better substrates for particular E3 ubiquitin 
ligases (and therefore better substrates for degradation) or protein 
phosphatases (  Yi et al., 2005  ;   van Drogen et al., 2006  ;   Yeh et al., 
2006  ;   Wu et al., 2007  ;   Yeh and Means, 2007  ). Proteins such as 
c-Myc, cyclin E, and SRC-3 use a common Pin1-interacting mo-
tif to facilitate turnover by the E3 ligase Fbw7. As this motif does 
not exist in SMRT, it is likely that a different E3 ligase may be 
involved. Thus, identifi  cation of components of the degradation 
machinery responsible for Pin1- and Cdk2-dependent SMRT 
degradation warrants further investigation and may reveal poten-
tial new therapeutic targets for treatment of certain breast cancers. 
  Phosphorylation of SMRT by Cdk2 may participate in 
some integral aspect of cell cycle regulation. Certain genes re-
quired for cell cycle progression may require removal or degrada-
tion of SMRT from their promoters in order for cells to proliferate. 
Another interesting hypothesis is that SMRT may play roles other 
than that of a corepressor as recent studies have indicated, includ-
ing involvement in DNA damage repair pathways and cell cycle 
regulation (  Li et al., 2006  ;   Yu et al., 2006  ). Additionally, it will be 
important to explore other potential regulators of SMRT stability 
and activity that may play a role in human development and dis-
ease generation or progression. Our observation that cyclin E co-
immunoprecipitated SMRT but not Cdk2 is intriguing. This could 
be caused by the inaccessibility of the epitope by cyclin E anti-
bodies. Alternatively, but not exclusively, these data suggest that 
the association of cyclin E with SMRT is independent of Cdk2. 
It will be interesting to further investigate the functional signifi  -
cance of the association between SMRT and cyclin E. 
  The ability of Pin1 to control SMRT protein levels ap-
pears to be cell type dependent, as Pin1 knockdown signifi  -
cantly increases SMRT protein steady-state levels in HeLa but 
not in BT-474 cells (  Fig. 2 D   and   Fig. 7 D  ). In contrast, knock-
down of Cdk2 increases SMRT protein levels in both HeLa and 
BT-474 cells (  Fig. 6 E   and   Fig. 7 D  ). These observations suggest 
that Cdk2 may use Pin1-dependent or -independent pathways to 
promote SMRT degradation. ErbB2 activation stimulates Cdk2 
activity, and knockdown of Cdk2 signifi  cantly increases steady-
state levels of SMRT proteins and blocks ErbB2-mediated SMRT 
degradation, indicating that Cdk2 is an integral component in 
the ErbB2-dependent SMRT degradation pathway. Notably, 
knockdown of Cdk2 abolishes ErbB2-activated gene expression 
(  Fig. 7 E  ) and cell proliferation (  Fig. 7 F  ). Our data favor an 
oncogenic role for Cdk2 in SMRT destabilization and suggest 
that decreases in SMRT protein levels correlate with relief in 
gene repression and increases in proliferation, both indicators of 
tamoxifen resistance, whereas increases in SMRT levels correlate 
with tamoxifen sensitivity. 
to coactivators, thereby elucidating part of the potential mecha-
nism underlying tamoxifen resistance and aberrant transcrip-
tional regulation in breast cancers. 
  Our studies clearly demonstrate that SMRT has distinct 
functions from N-CoR, as knockdown of SMRT is suffi  cient to 
desensitize cells to tamoxifen-mediated inhibition of PR and 
c-Myc expression and cell growth. Furthermore, overexpression 
of Pin1 in MCF-7 cells decreases SMRT protein levels but not 
N-CoR. Indeed, recent studies show that these two corepressors 
can be targets of different cellular pathways (  Jepsen et al., 2000, 
2007  ;   Jonas and Privalsky, 2004  ;   Yu et al., 2006  ), including 
growth factor signaling, DNA damage response, and normal 
mammalian development, and likely regulate some nonoverlap-
ping genes. As mentioned previously, knockdown of both SMRT 
and N-CoR is required to overcome the antiproliferative effects 
of tamoxifen in MCF-7 cells (  Keeton and Brown, 2005  ). Further-
more, N-CoR protein levels are decreased in tamoxifen-resistant 
tumors from a mouse model (  Lavinsky et al., 1998  ). This indi-
cates that a global decrease in corepressor expression is required 
for breast cancer progression and that there is an analogous path-
way leading to the accelerated degradation of N-CoR in ErbB2-
positive/tamoxifen-resistant breast cancers. It is probable that 
ErbB2-positive/tamoxifen-resistant breast cancers exploit a nor-
mal cellular pathway leading to the degradation of SMRT. 
  Pin1 has been shown to collaborate with several kinases to 
modulate protein stability, including MAPK, GSK3    , Cdk1, and 
Cdk2 (  Ryo et al., 2001  ;   Yeh et al., 2004, 2006  ;   Pastorino et al., 
2006  ). Our observation that Cdk2 phosphorylates SMRT to regu-
late its abundance supports the idea that Pin1 exerts diverse 
functions in different signaling pathways. We hypothesize that 
compartmental and temporal regulation of the association be-
tween Pin1 and its targets fi  ne tunes Pin1 activity. For example, 
several Pin1-mediated degradation pathways are likely to be 
cell cycle dependent, as multiple cell cycle regulatory proteins 
are involved (  Yeh and Means, 2007  ). It will be highly informa-
tive to explore whether SMRT protein levels are regulated in a 
cell cycle  –  dependent manner, as has been suggested previously 
(  Park et al., 1999  ). Like SMRT, N-CoR also contains seven con-
sensus Cdk phosphorylation sites. However, of the three sites 
identifi  ed here, only serine 1469 (S1469) is not conserved be-
tween SMRT and N-CoR. Intriguingly, S1469 is the phosphoryl-
ation site that does not change in response to Cdk2 overexpression. 
Therefore, it is likely that there are other kinases that may play 
a role in this complex regulatory pathway. 
  Pin1 is thought to be an important regulator of tumorigen-
esis and is overexpressed or underexpressed in different tumors 
( Bao et al., 2004 ;  Mantovani et al., 2007 ;  Yeh and Means, 2007 ); 
thus, it can potentially act as either an oncogene or a tumor-
suppressor gene, depending on cellular context. ErbB2 activation 
stimulates Pin1 transcription, and in turn Pin1 stimulates the 
transformative properties of ErbB2-positive cells (  Ryo et al., 
2002  ). Interestingly, although activation of ErbB2 decreases 
SMRT protein levels in BT-474 cells, Pin1 knockdown does not 
affect SMRT levels (  Fig. 7 D  ). However, knockdown of Pin1 
sensitizes cells to tamoxifen-mediated repression of c-Myc and 
PR expression without affecting BT-474 cell proliferation (  Fig. 7, 
E and F  ). These data suggest that Pin1 may affect tamoxifen 59  REGULATION OF SMRT STABILITY   • Stanya et al. 
  Transient transfection reporter assays 
  CV-1 cells were cotransfected with 16.6  –  66.6 ng pCMX-Gal4 and pCMX-
Gal4-SMRT (1,060  –  1,823) constructs (  Nagy et al., 1997  ), 100 ng 
pMH100  –  thymidine kinase  –  Luc, and 100 ng pCMX-LacZ in DME growth 
medium using Lipofectamine. The amount of DNA in each transfection 
was kept constant by the addition of parachlorometaxylenol. Cells were 
harvested and assayed for luciferase activity 36  –  48 h after transfec-
tion. The luciferase activity was normalized to the     -galactosidase activity. 
Each transfection was performed in triplicate and repeated at least 
two times. 
  In vitro kinase assays 
  GST-SMRT (1,178  –  1,578 and 1,560  –  1,823) constructs were puriﬁ  ed from 
  E. coli   and incubated with puriﬁ  ed Cdk2 (New England Biolabs, Inc.) ac-
cording to the manufacturer  ’  s protocol. In brief, equal amounts of puriﬁ  ed 
GST-tagged proteins were incubated with 100 U of puriﬁ  ed Cdk2  –  cyclin A 
complexes in the associated buffer (NEB) for 30 min at 30  °  C. For auto-
radiography, [ 
32  P]ATP (PerkinElmer) was used. Reactions were stopped with 
SDS-PAGE sample buffer, separated by SDS-PAGE, transferred to polyvinyl-
idene diﬂ   uoride membrane, and subjected to autoradiography, immuno-
blotting (anti-GST; Santa Cruz Biotechnology, Inc.), or Coomassie staining. 
  Mass spectrometry 
  HeLa WCEs transfected with FLAG-SMRT (1,178  –  1,823) and treated with 
20 nM calyculin A were subjected to coimmunoprecipitations using anti-
FLAG afﬁ  nity beads (Sigma-Aldrich) and separated by SDS-PAGE. The gel 
was Coomassie stained, and protein bands were cut out, washed and de-
stained (50% ethanol and 5% acetic acid), reduced and alkylated (DTT 
and iodoacetamide), dehydrated (acetonitrile), and dried in a speed vac. 
Samples were digested using trypsin (20 ng/  μ  L in 50 mM ammonium 
bicarbonate), and peptides were analyzed by liquid chromatography-mass 
spectrometry (linear ion trap; Finnigan LTQ). 
  Pulse-chase labeling 
  Cells were starved 10 min before labeling with DME lacking cysteine and 
methionine. Cells were then pulse labeled for 30 min with DME containing 
[ 
35  S]Met/Cys (PerkinElmer), washed twice, and chased in DME with un-
labeled Met/Cys for the indicated times. Before labeling, cells were treated 
with either 100 ng/ml heregulin (R  &  D Systems) or 0.1     M AG825 (EMD) for 
30 min. Cells were lysed, and WCEs were subjected to immunoprecipitation 
overnight with either anti-SMRT (our own) or anti-HA antibodies (Sigma-
Aldrich), separated by SDS-PAGE, and analyzed by autoradiography. Bands 
were quantiﬁ  ed using an imaging system (VersaDoc; Bio-Rad Laboratories). 
  Immunoﬂ  uorescent microscopy 
  Immunoﬂ   uorescent staining was performed at room temperature as de-
scribed previously (  Reineke et al., 2008  ) using the antibodies anti-SMRT 
(ABR) and anti-FLAG (Santa Cruz Biotechnology, Inc.). N-CoR antibodies 
were puriﬁ  ed in our laboratory. Secondary antibodies (conjugated to Alexa 
Fluor 488 or 594) were purchased from Invitrogen. Coverslips were mounted 
using mounting medium with DAPI (Vectashield; Vector Laboratories). Cells 
were analyzed using a ﬂ  uorescent microscope (DMLB; Leica) using a 40  ×   
lens (Leica) with a numerical aperture of 506744. Images were captured 
with a camera (7.2 Color Mosaic; Diagnostic Instruments, Inc.) and acquired 
using SPOT Advanced (Diagnostic Instruments, Inc.). 
  RT-PCR 
  BT-474 cells were transfected with siRNA as described in Cell culture and 
transfection. 48 h after transfection, cells were treated with 100 nM 4-hydroxy-
tamoxifen (Sigma-Aldrich) or ethanol vector control. 72 h after treatment, total 
RNA was harvested using PrepEase RNA Spin kits (USB). cDNA was gener-
ated using Superscript II reverse transcription and oligo-dT primers (Invitrogen). 
PCR reactions were performed using the following primers: 36B4 forward 
5    -TGTTTCATTGTGGGAGCAGAC-3    , 36B4 reverse 5    -A  A  G  CA  CTT  CAG  G-
GTTCTAGAT-3    , c-Myc forward 5    -ATGAAAAGGCCCCCAAGGTAG  TTAT-3    , 
c-Myc reverse 5    -GCATTTGATCATGCATTTGAAACAA-3    , PR forward 5    -CC  A-
TGTGGCAGATCCCACAGGAGTT-3    , and PR reverse 5    -T  G  G  AA  AT  TCA  ACA-
CTCAGTGCC-3    . Quantiﬁ  cation was performed in Photoshop (Adobe). 
  Cell proliferation 
  BT-474 cells were transfected with siRNA as described for RT-PCR. 48 h af-
ter transfection, cells were counted, and 1,500 cells were plated into 96-well 
plates. Cells were treated with either 100 nM 4-hydroxytamoxifen or etha-
nol vehicle control. The day 0 time point was taken     12 h after plating. 
Cell proliferation was measured every 24 h using the CyQUANT NF Cell 
Proliferation Assay kit (Invitrogen). 
  Materials and methods 
  Yeast methods 
  Yeast two-hybrid screens and assays were performed using standard meth-
ods described previously (  Kao et al., 2000  ). A yeast two-hybrid library 
from mouse 17-d-old embryos (Stratagene) and pGBT9-hSMRT (a region 
encompassing amino acids 1,060  –  1,823 of human SMRT) were cotrans-
formed into the yeast strain Y190. Approximately 5   ×   10 
6   yeast transform-
ants were screened and selected on yeast minimal medium Leu-Trp-His 
plates containing 40 mM 3-aminotriazole (Sigma-Aldrich). After 7 d, col-
onies were picked, and the interactions were conﬁ  rmed by     -galactosidase 
assays. Plasmids were recovered from the yeast and retransformed into 
yeast along with the bait construct. Positive clones were subjected to se-
quencing. Liquid     -galactosidase assays were performed as described by 
the manufacturer (Clontech Laboratories, Inc.), and the data represent the 
mean of duplicate reactions of two colonies. 
  Plasmid construction 
  pGBT9-SMRT yeast two-hybrid plasmids have been previously described 
(  Kao et al., 2000  ). Pin1, Cdk2, and cyclin A expression vectors were gen-
erated by PCR from a HeLa library and subcloned into the CMX-1F or -1H 
vector (  Gao et al., 2006  ). HA full-length SMRT and HA-SMRT (1  –  1,178) 
were derived from previously described plasmids (  Park et al., 1999  ); HA-
SMRT (1,012  –  2,507), HA-SMRT (1,823  –  2,507), and HA- and FLAG-SMRT 
(1,178  –  1,823) were derived from previously described plasmids (  Chen 
and Evans, 1995  ). GST  –  Pin1, GST-SMRT (1,178  –  1,578), and GST-SMRT 
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